Detalhe da pesquisa
1.
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Oncologist;
2024 Jun 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38828490
2.
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Oncologist;
2024 Jun 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38837045
3.
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
JAMA;
331(20): 1714-1721, 2024 05 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38683596
4.
Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study.
Support Care Cancer;
31(8): 450, 2023 Jul 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37421495
5.
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Future Oncol;
17(34): 4665-4676, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34636255
6.
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Cancer;
126(5): 1060-1067, 2020 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31943168
7.
Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Gynecol Oncol;
159(3): 611-617, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33059914
8.
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Pharmacogenet Genomics;
27(11): 402-409, 2017 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28877533
9.
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Oncologist;
21(7): 795-803, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27226358
10.
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Br J Clin Pharmacol;
80(5): 1122-30, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25907378
11.
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer.
medRxiv;
2023 Dec 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38106014
12.
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Commun Med (Lond);
3(1): 14, 2023 Feb 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36750617
13.
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Cancer Res Commun;
3(7): 1335-1349, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37497337
14.
Tamoxifen and CYP2D6: a contradiction of data.
Oncologist;
17(5): 620-30, 2012.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22531359
15.
Assessing the utility of whole genome amplified DNA as a template for DMET Plus array.
Clin Chem Lab Med;
50(8): 1329-34, 2012 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22868796
16.
Symptom management in metastatic breast cancer.
Oncologist;
16(9): 1203-14, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21880861
17.
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Invest New Drugs;
29(5): 978-83, 2011 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20387090
18.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
J Immunother Cancer;
9(8)2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34429332
19.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
J Clin Oncol;
39(35): 3938-3958, 2021 12 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34324366
20.
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
JCO Precis Oncol;
52021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34476329